Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gerlach

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Brain : a Journal of Neurology|June 27, 2023
The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSifat Sharmin, Izanne Roos, Steve Simpson-Yap, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosisCyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
JAMA Neurology|April 14, 2025
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Pageof 6